All In Biotech

Drug Trial Radar · NCT03128164

A Study of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or no Standard of Care Existed

A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Lymphomas Failed of Standard of Care or No Standard of Care Existed

Last checked: Nov 19, 2026Latest source record: Aug 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

200

Actual

Start

Aug 8, 2017

Primary completion

Aug 2, 2023

Study completion Aug 2, 2023

Sponsor

Lead sponsor
Hutchison Medipharma LimitedIndustry
Sponsor type
Industry
First posted
Apr 25, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label study of HMPL-689 administered orally to patients with lymphoma for whom failed of standard care or have no standard of care.This study consists of a dose escalation stage (Stage I) and a dose expansion stage (Stage II).

Conditions

  • Lymphomas

Interventions

  • HMPL-689Drug

    Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limited toxicities evaluated with NCI CTCAE v4.03Time frame: within 28 days after the first dose
  2. Objective response rate (ORR)Time frame: Through study completion, 1 year after the last patient has enrolled in the study or all patients have discontinued the study, whichever comes sooner

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University cancer center

    Guangzhou, China

  • Fudan University Shanghai Cancer Center

    Shanghai, China

  • TongJi Medical College Huazhong University of Science& Technology

    Wuhan, Hubei, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.